financetom
Business
financetom
/
Business
/
Encouraging foreign brands to return to Russia 'ill-advised', trade ministry says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Encouraging foreign brands to return to Russia 'ill-advised', trade ministry says
Feb 20, 2025 3:04 AM

Feb 20 (Reuters) - Encouraging foreign brands to return

to Russia would be "ill-advised," according to the industry and

trade ministry, which wants to champion domestic companies that

have stepped in to fill the gaps left by departing Western

counterparts.

More than a thousand companies, from McDonald's to

Mercedes-Benz, left Russia in the last three years by

selling, handing the keys to existing managers, or abandoning

assets.

Others like Danone and Carlsberg had

their assets seized and a sale forced through.

But as Moscow and Washington discuss a path to end the war

in Ukraine, one of the many questions on investors' minds is

whether the corporate exodus from Russia, triggered by the

February 2022 invasion of its neighbour, may be reversed.

"The Ministry of Industry and Trade considers it ill-advised

to stimulate the return of foreign brands," it said in a

statement to Reuters on Thursday.

"In the last three years, domestic companies have

significantly increased their own production and actively

occupied market niches vacated after the exit of foreign

companies."

Russian businesses have been successfully importing

requisite goods through indirect means, the ministry said, and

its absolute priority was protecting domestic producers and the

production of high-quality products on Russian soil.

French automaker Renault, which agreed a six-year

buyback option when selling its majority stake in Russian

carmaker Avtovaz in May 2022, on Thursday said the probability

of activating its clause with Avtovaz was "very, very low."

"If any foreign company decides to return to the Russian

market, then this issue should be considered on an individual

basis," the ministry said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AMTD's IDEA Group, Units Agree to Merge With Special Purpose Acquisition Company to Bring WME Subsidiary Public
AMTD's IDEA Group, Units Agree to Merge With Special Purpose Acquisition Company to Bring WME Subsidiary Public
Jan 27, 2025
10:04 AM EST, 01/27/2025 (MT Newswires) -- AMTD Group's IDEA Group (AMTD) and AMTD Digital ( HKD ) have agreed to merge their World Media and Entertainment Universal subsidiary with special purpose acqusition company Black Spade Capital's subsidiary Black Spade Acquisition II ( BSII ), to bring World Media and Entertainment public. The deal values WME at an equity value...
MicroStrategy's Strike Preferred Stock Offering Fuels Bitcoin Acquisition Plans: Details
MicroStrategy's Strike Preferred Stock Offering Fuels Bitcoin Acquisition Plans: Details
Jan 27, 2025
The business intelligence and Bitcoin-focused company MicroStrategy Incorporated ( MSTR ) shares are trading lower on Monday. The company disclosed plans to offer 2.5 million shares of its Series A Perpetual Strike Preferred Stock in a public offering. The company expects to use proceeds for general corporate purposes, including bitcoin acquisitions and working capital. MicroStrategy’s perpetual strike preferred stock carries...
Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design
Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design
Jan 27, 2025
10:01 AM EST, 01/27/2025 (MT Newswires) -- Cartesian Therapeutics ( RNAC ) said Monday the US Food and Drug Administration has agreed to the design of its phase 3 AURORA trial for Descartes-08, its mRNA cell therapy for myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness. The company said the randomized trial, expected to begin in H1, will...
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk to cap insulin prices in Minnesota settlement
Jan 27, 2025
Jan 27 (Reuters) - Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of deceptive pricing practices, court papers on Monday show. The settlement calls for Novo Nordisk to cap monthly out-of-pocket costs at $35 per prescription for patients who want it. Novo Nordisk also intends to...
Copyright 2023-2025 - www.financetom.com All Rights Reserved